Animalcare Share Discussion Threads

[p1nkfish] 28/2/2024 08:07

There's always the risk the capital isn't allocated wisely but the CEO appears sensible overall with a keen focus on cash conversion and stable growth. My target (I don't have a timescale) is £4+. Dyor etc, I'm often wrong.

Do suspect they have some targets for the cash lined-up.

[p1nkfish] 28/2/2024 07:52

From the latest preliminary financial update: "The Group ended the financial year in a net cash position, pre IFRS16 leases, of £1.7 million, (31 December 2022: £2.4 million debt). This very strong financial platform enables the pursuit of inorganic and organic opportunities that support the Group's long-term growth strategy."

Today after Identicare sale: "........cash consideration of £24.9m (the "Consideration") payable upon completion of this sale........Upon receipt of the Consideration and after fees associated with the transaction, the Company's net cash is expected to be around £27.0m."

About £116M market cap with net cash of £27M and £74.4M revenue last year with strong cash conversion, lose about £3M revenue from Identicare (haven't checked if profit contribution, certainly was growing & probably a decent margin).

Now more focussed. See if it garners interest in the next few weeks prior to results on 9th April.

Still a lovely and quiet PBB.

[1c3479z] 28/2/2024 07:33

Excellent if they use the money wisely,

[p1nkfish] 28/2/2024 07:31

Indenticare disposal and now a stronger balance sheet loaded up with cash.
I wasn't expecting a change this quickly.
Good news overall and now focus on core business growth.

"Jenny Winter, Chief Executive Officer commented: "I'm very proud to see what we have achieved with Identicare in recent years. Today's decision to crystallise the value from the sale is the logical next step, significantly strengthening our balance sheet and giving us additional financial flexibility and firepower as we concentrate on growing our pharmaceutical-focused animal health business.""

[p1nkfish] 08/2/2024 16:39

May pullback but looking like a breakout and still lovely and quiet.

[p1nkfish] 07/2/2024 12:26

May not be this week but getting there.

[p1nkfish] 02/2/2024 13:19

Slowly moving, weekly close above 189p then a new phase imho, dyor etc.

[p1nkfish] 30/1/2024 19:07

Lovely and quiet here, just how I like it.

[p1nkfish] 25/1/2024 12:41

With some developments on the consumer side this could really show some growth.
CEO appears to be very capable.
More I dig tge more I quite like the potential, steady growth and now no bet debt. Dyor etc, I'm often wrong.

[p1nkfish] 25/1/2024 07:15

TU confirms now net cash, turned a corner, ready for next stage of development.
Patience needed but looking decent.

[p1nkfish] 12/1/2024 17:58

I see a much brighter future here than many might think, dyor though as I'm often wrong. Have been delving into this and taken a position recently as a wait and hold. Good little UK company, we need more like this.

[p1nkfish] 29/12/2023 11:05

ANCR has some interesting hallmarks and looks relatively unloved. Sentiment can change with improved results.

[typo56] 10/11/2022 15:28

Looking firm today. Someone had to pay 246 for 23k when spread 215/230. Now you can sell 10k at 235p when spread 225/235. Go figure!

[km18] 26/11/2021 12:55

From WealthOracleAM....

Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently.
Other than the “underappreciated” by investors investment in 2017, the Group has been performing rather well. They have reduced their debt and increasing the cash generated from operations, thus gearing is minuscule at 16%. Revenue is growing at 39.1% CAGR, ROCE at 4.52% and dividends were doubled in 2020 from 2019, so there is plenty of return for the investors. However, ANCR remains very highly priced, with P/S just below the industry average and EV/EBITDA being quite high at 25.09.

[wjccghcc] 08/7/2021 14:09

It is 23% of the company and the placing price is where the share price was 6 weeks ago so the discount is not that surprising.

It’s clear that Cardon has been wanting to move onto other things since he gave up being CEO in 2018 and then moved to non exec in 2019.

At least the overhang is gone now.

[pugugly] 08/7/2021 13:28

Secondary placing - Hit share price very hard. Views?
8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021

[trcml] 10/6/2021 14:47

Nice uplift since I bought during the first week of May. Our vet uses ANCR products:when i mentioned the imminent release of a new product, the vet was very interested . Suppliers of products to vets are onto a good thing.

[bunz3] 21/1/2021 14:39

that video now on ggp share board , a good example for other shares

[energeticbacker] 21/12/2020 10:25

The growth in pet ownership over lockdown and owner’s desires to keep their pets fit and healthy has been great news for the pet care sector. However, who are going to be the long-term winners from the current pet boom?

Investor’s Champion’s research highlights some terrific companies which should continue to do well, including a star performer. #ancr #chwy #cvsg #elan #idxx #nesn #pets #zts

[8craggle] 13/10/2020 11:03

The website identibase is in complete disarray at present, shambolic. Vets, animal charities and private individuals unable to register chips they have paid for.Fraudulent incompetence over the last few weeks

[energeticbacker] 30/9/2020 08:34

The latest interim results suggest that the efforts of newish CEO Jenny Winter appearing to be bearing fruit, despite the short term disruptions.

Revenue declined 4.4% to £34.5m due to the impact of the pandemic, with largest product category of Companion Animals seeing a 10.6% decline to £21.2m and Production animals seeing 13.1% growth to £10.5m. Equine and other declined 10% to £2.7m.

More on the Investor's Champion website.

[pugugly] 21/6/2020 14:05

The full statement from the auditor's report - Hedging opinion (imo)

Material uncertainty related to
going concern – Group and Parent
Company
In forming our opinion on the financial
statements, which is not modified, we have
considered the adequacy of the disclosure
made in note 3 to the group financial
statements and note 1 to the parent
company’s financial statements concerning
the group’s and parent company’s ability to
continue as a going concern.
The Group’s forecast cash flows contain
assumptions over revenue, profitability
and cash generation. These forecasts have
been stress-tested for severe but plausible
scenarios that could impact the Group.
These show that in a more prolonged severe
downturn there may be a potential breach
of the leverage covenant for the Group’s
borrowing facility. If such a breach were
to occur the Group would need to obtain
a covenant relaxation or waiver from the
Group’s banking syndicate. This condition,
along with the other matters explained in
note 3 to the financial statements, indicates
the existence of a material uncertainty which
may cast significant doubt about the group’s
and parent company’s ability to continue as
a going concern. The financial statements
do not include the adjustments that would
result if the group and parent company were
unable to continue as a going concern.
Explanation of material uncertainty
Management and the Board considered the
potential impact of COVID-19 on the current
and future operations of the business. In
doing so, management focused on the
Group’s ability to continue as a going concern
by performing a detailed bottom-up analysis
of the impact of COVID-19 on revenue,
EBITDA and cashflows. Management made
estimates and judgements that are critical to
the outcome of these considerations. Three
scenarios were modelled – a new base case
and two further downside scenarios. This
analysis has been used in conjunction with
an assessment of the Group’s liquidity and
consideration of loan covenants.
Audit procedures performed
In assessing management’s consideration
of the potential impact of COVID-19, we
undertook the following procedures:
• We obtained management’s board
report that details the Group’s
assessment and conclusions with respect
to their ability to continue as a going
concern;
• We assessed the initial 2020 (preCOVID-19) budget as well as the new
base case forecast and two further
downside scenarios (each of which factor
in COVID-19 overlays);
• We confirmed that the initial 2020 (pre
COVID-19) budget was board approved.
In addition, we evaluated the historical
accuracy of the budgeting process to
assess the reliability of the data;
• In relation to the COVID-19 overlays, we
held discussions with management to
understand and challenge the rationale
behind the assumptions made, using our
knowledge of the business and industry;
• We reviewed the latest trading results for
the year to date in 2020 and compared
to management’s original budget,
FY19 actuals and revised forecasts, and
considered the impact of these actual
results on the future forecast period;
• We understood the mitigating actions
taken by management, including
suspending the final dividend payment;
• We reviewed management’s sensitivity
scenarios and we challenged
management to run further downside
scenarios in order to assess the possible
impact of headroom against their
borrowing facilities; and
• We reviewed the disclosures included
within the Annual Report and consider
these to be appropriate.